Despite Landing Biggest PBM Formularies, Celltrion’s Zymfentra Not Listed By US Insurers
Zymfentra Is The First FDA-Approved Subcutaneous Formulation Of Infliximab
Celltrion gave updates on several business aspects and reassured its shareholders that the delayed insurance listing for Zymfentra will not affect its set annual sales goal.
